References
- European Medicines Agency. Zyprexa: EPAR – Product Information. London: European Medicines Agency; 2009 [updated June 7, 2013; cited June 11, 2013]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/000115/human_med_001189.jsp&mid = WC0b01ac058001d124. Accessed June 11, 2013.
- Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64:5–19.
- Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003; 15:181–186.
- Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol 2003; 26:58–61.
- Reich J. Use of high-dose olanzapine in refractory psychosis. Am J Psychiatry 1999; 156:661.
- Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003; 64:663–667.
- Liu X, De Haan S. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev 2009; 15: CD007778.
- Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19:520–532.
- Mental Health Services - Capital Region of Denmark. Available from: http://www.psykiatri-regionh.dk. Accessed June 11, 2013.